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Characterization of soluble E-cadherin as a disease
marker in gastric cancer patients
J Gofuku, H Shiozaki, Y Doki, M Inoue, M Hirao, N Fukuchi and M Monden
Department of Surgery 11. Osaka University Medical School. 2-2 Yamadaoka Suita. Osaka. 565. Japan
Summary The soluble fragment of E-cadherin protein (S-ECD) is reported to be increased in the peripheral blood of cancer patients. In this
study. we investigated the clinical significance of serum S-ECD in 81 patients with gastric cancer. The amount of serum S-ECD was
significantly higher in the gastric cancer patients (4735 ± 2310 ng ml-) than in healthy volunteers (2515 ± 744 ng ml-). With the normal range
cut-off at average +2 s.d., 67% patients showed abnormally high serum S-ECD levels. This frequency was significantly higher than that of
other tumour markers, such as CEA (4.40o) or CAl9-9 (13.3%). However, there was no significant correlation between the amount of S-ECD
and clinicopathological factors. Serum S-ECD might be derived from cancer tissue, as removal of cancers by surgical treatment results in
quick decline of the serum S-ECD and S-ECD can be detected by immunoblot in cancer tissues but not in normal epithelium. The serum
S-ECD amount was compared with the E-cadherin expression in cancer tissues, which were classified into those showing preserved (+),
partially reduced (±) or lost (-) expression. Interestingly, E-cadherin (±) tumours showed higher serum S-ECD levels than the othertypes, and
a higher amount of S-ECD in the immunoblot analysis. Thus, the serum level of S-ECD may serve as an excellent tumour marker with high
sensitivity. Furthermore, analysis of S-ECD in serum and cancer tissue can offer clues for elucidating the mechanism of reduction of
E-cadherin expression in cancer cells.
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E-cadherin plays an essential role in the maintenance of cell-cell
adhesion of epithelial cells by homophilic interaction (Takeichi.
1991). Reduction in E-cadherin is frequentlI observed in cancer
cells and is strongly associated w-ith tumour invasion and metas-
tasis (Shiozaki et al. 1996). E-cadherin is a familv of transmem-
branous glycoproteins with an amino terminus in the extracellular
domain to bind to another E-cadherin in an adjacent cell. and a
carboxv terminus that is connected to the cvtoskeleton through
catenins (Ozawa et al. 1989). Full-length E-cadherin (120 kDa
has a cleavage site near the transmembrane domain and artificiall1
produces a soluble 80-kDa amino-terminal fragment in the culture
medium on trypsin dicestion (Damskv et al. 1983). This soluble E-
cadherin frarment (S-ECD) is also observed in the protein extract
of tissue samples. the serum of peripheral blood (Katayama et al.
1994a) and the urine (Katavama et al. 1994b).
Recently. soluble protein fragments of various adhesion
molecules. such as intercellular adhesion molecule-1 (ICAM-1)
(Reinhardt et al. 1996). vascular cell adhesion molecule-1
(VCAM-1) (Banks et al. 1993). E-selectin (Schadendorf et al.
1996). PI integrin (Katayama et al. 1991) and CD44 (Jung et al.
1996). were detected in serum b- the enzvme-link-ed immunosor-
bent assay (ELISA) method. and their association u-ith disease has
been w-ell discussed. Serum S-ECD is reported to be increased in
hepatitis (Katayama et al. 1994a). inflammators bowel disease (H
Shiozak-i. unpublished obsenration). skin disease (IMatsuvoshi et
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al. 1995) and -arious cancers (Katavama et al. 1994a: Griffiths et
al. 1996). On the other hand. E-cadherin expression in cancer
tissues is frequently decreased or showvs no increase (Shiozaki et
al. 1991). This difference between serum S-ECD and E-cadherin
expression of cancer cells suggests that S-ECD may be generated
in cancer tissues as a consequence ofaccelerated protein turnover.
In this studv. we examined the serum S-ECD level in gastric
cancer patients. in comparison A-ith healths s-olunteers. and
explored the possibility of serum S-ECD wvorking as a tumour
marker. Furthermore. vse demonstrated that serum S-ECD miaht
oriainate from cancer tissues based on results from immunoblot
and immunohistochemical analssis. These results also gave us
important clues towards understanding the mechanism of reduc-
tion ofE-cadherin expression. which is a characteristic of invasise
and metastatic cancer cells.
MATERIALS AND METHODS
Samples
Serum samples were obtained from 20 healthy control subjects
and 81 patients with gastric cancer w-ho unders-ent surgers. The
patients were 60 men and 21 sAomen w-ith a mean age of 63 years
(range 38-88 years). None of them had received anti-cancer
therapy before the operation. For 40 out of the 81 patients. serum
samples w-ere collected not only before the operation but also at
s-eeklv intersals after the operation until 21 post-operatisxe days.
For 44 patients. tissue samples of cancer nests sAere also available
for evaluation of E-cadherin expression in cancer tissue. The
pathological classification for gastric cancer was based on the
International Union Auainst Cancer Classification (UICC).
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Table 1 Association of serum S-ECD amount with clinicopathological
factors
Classiftation S-ECD level (ng mt') P-value*
T categories
Tl 4286 ±2363-
T2 5217 ±2398
T3 4841 ± 2001 0.298
T4 6697 ± 2206
N categones
NO 4617+2368
Ni 4869± 2392
N2 4742± 2324 0.859
N3 5783 ±1574
M Categories
MO 4829 ± 2347
Ml 3965±1931 0.321
Pathological stage
Stage 1 4334 2402
Stage 2 5370 ±2188
Stage 3 5109±2315 0.485
Stage 4 4511 ± 2183
'By two-factor factorial ANOVA. -Mean s.d.
Immunoenzymometric assay for soluble E-cadherin
Soluble E-cadhenrn levels were measured with a commercially
available sandwich-type enzyme immunoassav kit (Takara Shuzo.
Kyoto. Japan) using immobilized HECD-1 (Shimoyama et al.
1989) and enzyme-labelled SHE13-6 (Katayama et al. 1994a).
both of which were murine monoclonal antibodies against human
E-cadherin with distinct epitopes. The optical density ofeach well
was determined with a microplate reader (Thermo Max. Wako.
Japan) at the wavelength ofy= 490 nm. Measurement was done in
duplicate for each sample and the mean value was used.
Immunohistochemical detection for E-cadherin
Immunostaining for E-cadherin was performed by the avidin-
biotin-peroxidase complex method using HECD-I as described
previouslv (Shiozaki et al. 1991). In brief. serial frozen sections (4
im) of cryopreserved tissues were fixed with 3.6% parafonralde-
hyde in 0.1 M phosphate-buffered saline (PBS) (pH 7.4) for 30 min.
Primary antibody was applied and incubated overnight at 40C
sequentially. followed by biotinylated anti-mouse IgG and avidin
combined in vitro with horseradish peroxidase (Vector. Burlingame.
CA. USA). Slides were developed using diaminobenzidine supple-
mented with 0.02% hydrogen peroxide for4 min. The sections were
counterstained with haematoxylin. dehydrated and mounted.
The E-cadherin expression of cancer cells was compared with
that of normal epithelial cells. which always express E-cadherin
molecules in the same sample. The cancer cells with staining as
strong as that ofnormal epithelial cells were defined as positive. If
the staining was weaker or lost. the cells were defined as negative.
The grade of E-cadherin expression of the tumours was evaluated
according to the proportion of positive cells. When more than
90%. between 10% and 90% or less than 10% of the cancer cells
were positively stained, the tumours were evaluated as preserved
(+). reduced (±) and lost (-) respectively. A consecutive section
from each specimen was stained with haematoxvlin and eosin for
histological evaluation.
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Figure 1 S-ECD concentration in the sera of gastric cancer patents and
healthy volunteers. Serum S-ECD concentratons measured by the sandwich
IEMA method are shown with open circles (healthy volunteers) and closed
circles (cancer patients). Upper limit of normal range (mean +2 s.d.) are
indicated with dotted line. There was a statistically significant difference
between two groups (P < 0.0001)
Protein extraction and immunoblot analysis
Samples from cancer tissue and non-cancerous mucosa were
divided into two pieces and treated by two different extraction
methods. One was homogenized directly in sample buffer
containing 2% sodium dodecyl sulphate (50 ami Tris pH 7.5.
150 mm sodium chloride. 1 m-M PMSF. 4 jg ml-' aprotinin.
10 jiJml-' leupeptin) to extract the total tissue proteins. Another
piece was homogenized on ice in PBS containing the same
protease inhibitors. but without any detergent. to obtain the
soluble components in extracellular spaces. After centrifugation.
3x sample buffer was added to the supernatant. Proteins. applied
to each lane. were adjusted to equal concentrations using the Bio-
Rad protein assay kit. The resulting lysates were boiled for 5 min
in the presence of 5% 2-mercaptoethanol. fractionated by 7.5%
polyacrylamide gels and transferred to nitrocellulose sheets.
Next. immunoblotting analysis w-as performed with mAb
HECD-1. For antibody detection, the blotting detection kit (ECL
Western blotting detection reagents. Amersham Life Science.
UK) was used.
Statistical analysis
Welch's t-test or Fischer's exact probabilit) test was used to
compare the data of the different groups. To analyse the correla-
tion between clinicopathological factors and serum S-ECD levels
two-factor factorial ANOVA was used. The data are presented as
means ± s.d. Differences of P < 0.05 were considered to be statis-
ticallv significant.
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RESULTS
Soluble E-cadherin fragments in serum of gastric
cancer patients
S-ECD in the biological fluid can be detected by the sandwich
ELISA method and quantitized on a standard curve with recombi-
nant E-cadherin fragments. The immunoreactive S-ECD amount
in the serum of 20 healthy individuals was 2515 ± 744 ng ml-'
(mean ± s.d.), range 1026-3540 ng ml-'. On the other hand, the
average serum S-ECD concentration in the 81 gastric cancer
patients was 4735±2310ngml-' (mean±s.d., range 1134-10
208). Thus, serum S-ECD levels in gastric cancer patients were
significantly higher than in the healthy control individuals
(P<0.0001). In order to confirm the reproducibility, senrm samples
were taken again after a 1-week interval from ten patients, and
their serum S-ECD amount showed less than 10% difference
compared with the first sample. When the normal range was cut
off at the average +2 s.d. (4003 ng ml-'), 67% ofthe gastric cancer
patients showed higher serum S-ECD levels than this amount
(Figure 1). This sensitivity of serum S-ECD in the gastric cancer
patients was significantly higher than that of CEA (4.4%) or
CA19-9 (13.3%) for 45 randomly chosen patients whose serum
levels of CEA and CA19-9 were simultaneously measured in the
routine preoperative examination (Figure 2).
Next, the serum S-ECD amounts were compared with the
histopathological features of the 81 gastric cancer patients based
on UICC classification (UICC, 1987). Serum S-ECD gradually
increased with tumour invasion, though the findings were not
statistically significant. In addition, there was no significant corre-
lation between the preoperative serum level of S-ECD and lymph
node metastasis, distant metastasis and tumour staging (Table 1).
Tlhe effect of surgical removal of cancer was evaluated by
measuring serum S-ECD on post-operative days 7, 14 and 21, in
addition to the preoperative day, in 25 randomly chosen patients,
who showed serum S-ECD beyond the normal range (mean
+2 s.d.). Their serum S-ECD was 6324 ± 1697 ng ml-' at the
preoperative stage andgradually decreased aftersurgical treatment
(Figure 3). The difference was significant between preoperative
S-ECD and levels on days 7. 14 and 21. Pre- and post-operative
serum S-ECD was also measured in 15 gastric cancerpatients who
had normal S-ECD concentration. The effects of operation itself
on serum S-ECD seemed not so high, because serum S-ECD in
these patients remained in the normal range after operation
(preoperation 2637 ± 823 ng ml-'; post-operation day 7 1882 +
1063 ng ml-', day 14 2439 ± 1444 ng ml-l and day 21 2151 ± 1270
ng ml-').
Association of serum S-ECD with E-cadherin
expression and S-ECD in cancer tissue
T'he expressions ofE-cadherin in cancer tissues were evaluated by
immunohistochemistry in 44 cases out of 81 cancer patients, and
classified into the three categories as we described previously
(Kadowaki et al, 1994) (Figure 4). In 12 patients (27.3%, 12/44).
E-cadherin expression was preserved as found in normal epithe-
lium. There were two patterns in the reduction of E-cadherin
expression. The first was observed with 23 patients showing
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umour by surgery. Twenty-fe pafients wit high senm S-ECD were
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E-cadherin partially reduced (±) tumours which consisted of a
mixture ofE-cadherin-positive and -negative cells. The rest ofthe
patients were classified as E-cadherin lost (-) tumours, in which
E-cadherin was completely lost or weakly expressed in the cyto-
plasm. When the immunohistochemistry was compared with
serum S-ECD, E-cadherin partially reduced (±) tumours showed
A B
higher levels of serum S-ECD (6249 ± 1592 ng ml-') than
the preserved (+) (3353 ± 1902 ng ml-') or lost (-) tumours
(3402 ± 1659 ng ml-') (Figure 5).
Representative tumours ofthese three patterns were subjected to
Western blot analysis and the results are shown in Figure 6. Full-
length human E-cadhern and S-ECD were recognized at 120 kDa
and 80 kDa, respectively, in total tissue extrct with 2% sodium
dodecyl sulphate. The band around 100 kDa is considered to be
anotherdegraded formofE-cadherin, which is cleaved in the cyto-
plasm and not detected outside the cells (Covault et al, 1991).
Immunohistochemical expressions of E-cadherin were consistent
with the band of 120-kDa E-cadherin in normal squamous epithe-
lium and three different types of cancer tissues. S-ECD was
observed strongly in E-cadherin partially reduced (±) tumour and
preserved (+) tumour, and faindly observed in normal epithelium
and E-cadherin lost (-) tumour. The proportion of S-ECD against
120-kDa E-cadherin was highest in E-cadherin partially reduced
(±) tumour. S-ECD was concentrated in the extracellular fraction,
which can be obtained by mildhomogenization without any deter-
gents, and this fraction did not contain full-length E-cadherin,
which is bound to the cell membrane or exists in the cytosol. S-
ECD in this fraction was highest in E-cadherin partially reduced
(±) tumour, and lowest in normal epithelium and E-cadherin lost
(-) tumour. Thus, the amounts ofS-ECD in the extracellular space
ofcancertissues were similarto those in peripheral blood detected
by ELISA.
E-cadherin is a 120-kDa transmembrane glycoprotein which plays
a central role in intercellular adhesion ofepithelial cells (Takeichi,
1991). In the conditioned medium of cultured epithelial cells,
soluble fragments of E-cadherin (S-ECD) were detected at 80-
84 kDa and increased by tiypsin treatment (Ozawa et al, 1990).
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Figure 4 Vanous expression patters of E-cainerin the primary site of gastric cancer pabents. E-cadierin expresson were inkmunhstochec
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Figure 5 Companson between E-cadherin expression in the pnmary site
and S-ECD in peripheral blood. Serum S-ECD was significantly higher in the
patients with E-cadherin reduced (±) tumours than in the patients with other
expression pattems or healthy volunteers (P < 0.0001)
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Figure 6 Westem blot analysis of E-cadherin in normal and representative
gastric cancer tissue with three different E-cadherin expression pattems by
immunohistochemistry. Each 20 ug protein was extracted by two different
protein extraction methods: total protein extraction (T) and soluble
extracellular proteins (S) (see Materials and metiods). Arrow indicates ful-
length E-cadherin (120 kDa) and arrowhead indicates S-ECD (80 kDa)
Recently. txxo different antibodies against distinct epitopes of
E-cadherin hax-e been found and they enable measurement of S-
ECD by a sandxxich-type immunoenzymometric assay (IEMA)
(Katayama et al. 1994a). Using this assay system. S-ECD xas
detected in the serum (Katay ama et al. 1994a). unrne (Katayama et
al. 1994b). bulus fluid (Matsuyoshi et al. 1995) and bile juice (H
Shiozaki. unpublished obserxation). leading to study ofthe associ-
ation of S-ECD and diseases. In the present study. xxe demon-
strated that serum S-ECD may serxe as an excellent tumour
marker. as it was about twxofold higher in gastric cancer patients
than in healthy Xolunteers.
Soluble fraaments of adhesion molecules escaping into the
peripheral blood are sometimes utilized as tumour markers in
blood examination. Thev can be classified into twxo categories.
One is a group of adhesion molecules. xxhich is specifically ox-er-
expressed in cancer cells. For example. CEA. a member ofthe IgG
superfamily. binds to itself and to the extracellular matrix (Jessup
et al. 1993). CAI9-9 is sialyl Lewis A antigen and a ligand of E-
selectin (Majuri et al. 1992). SLX is also included in this group
(Phillips et al. 1990). The benefits of these proteins as tumour
markers are that thev haxe hiah specificitv for organs and malig-
nancies (Kax-ahara et al. 1985: Civardi et al. 1986). In addition.
w-hen thev are present. their amounts are usually large enough to
be easilv distinouished from those in the normal range. How-ever.
cancer cells do not always ox-erexpress these proteins and. there-
fore. the sensitixitv is sometimes not so high. especially ingastric
cancers (Staab et al. 1985).
A second group of adhesion molecules is not specific for cancer
cells. but usually expressed in normal and cancerous tissue.
Ho%vexer. their escape into the sNstemic circulation is stimulated in
cancer patients. probablv because of acceleration of turnoxer or
degradation of the protein. E-selectin (Schadendorf et al. 1996).
ICAM-I (Reinhardt et al. 1996). VCAM (Banks et al. 1993). CD44
(Jung et al. 1996) and laminin (Brocks et al. 1986: Katavama et al.
1992) haxe been included in this categ!ory. as has the S-ECD ofthis
studv. The sensitixity of S-ECD in gastric cancer patients wxas
67%7. which is significantly higher than that of CEA or CAl9-9.
Moreox er. this X alue is also higher than that ofother proteins ofthe
same group. including ICAM-1 in colon cancer (Reinhardt et al.
1996) or NCAM in lung cancer (Ledermann et al. 1994).
Clinical application of these proteins as a tumour marker
remains difficult. because they are not cancer or organ specific. In
particular. inflammatory disease is associated xx-ith the increase in
the amount of serum of these molecules. In the case of S-ECD.
inflammation of E-cadherin-rich organs such as lixer (Katayama
et al. 1994a). skin (Furukaxxa et al. 1994) or digestixe tract (H
Shiozaki. unpublished data) is concomitant wxith the high amount
of serum S-ECD. Helicobactor pylori gastritis is strongly associ-
ated with gastric cancer in Japan. Howexer. the S-ECD levels
among the patients wxere not higher than those of the normal
controls (3024±1134 ng ml-' xs. 2515+ 744 no m ). Exen ifthe
inflammator- diseases are excluded. the primarx sites of the
cancers cannot be determined only from the S-ECD amount. Thus.
serum S-ECD is increased not only in gastric cancer but also in
cancer ofthe colon (Katavama et al. 1994a). lix-er (Katavama et al.
1994a). pancreas (Katayama et al. 1994a) and oesophagus (H
Shiozaki. unpublished data). Interestingly. S-ECD wxas not
increased in the non-epithelial malignancies. such as leukaemia or
leiomr osarcomas (Katayama et al. 1994a). Thus. one should
suspect the presence of cancer or sexere inflammation in the
epithelial tissue for patients with S-ECD levels much hiaher than
the normal range (axerage +2 s.d. 4003 ng ml- ).
Serum S-ECD decreased folloxwing, the remoxval of tumours by
surgery. Western blot analdsis showxed the presence of S-ECD
mostlxr in cancer tissue and not in normal epithelium. This is
evidence that S-ECD A-as produced in cancer tissue and spread
into the sy stemic circulation. What seems strange is that wxe could
not find any si2nificant correlation wxith pathological factors.
including depth of invasion. lymph node metastasis and peritoneal
dissemination. We speculate that the dixersitx of the tumour char-
acteristics might contribute to the amount of serum S-ECD more
than the x-olume or adx anced stage of the cancer. In fact. serum S-
ECD was increased in 40%-e of superficial cancers. In addition. it is
xerv interesting, that serum S-ECD and the depth of inxasion
showed sianificant correlation in colon cancer (unpublished obser-
xation). in which the expression of E-cadherin is more frequently
preserxed (Nigam et al. 1993) than in gastric cancers (Oka et al.
1992) (preserxedtype 71 7c xs.421c).
In order to find support for our hypothesis that tumour charac-
teristics related to E-cadherin expression affects the serum
S-ECD amount. xxse compared the serum S-ECD amount with the
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immunohistochemical expression of E-cadherin in cancer tissues.
In a previous study. we had noticed that there were tmo different
patterns in the reduction of E-cadhenrn expression in gastric
cancer. In the present study. we classified the tumours into E-
cadherin preser-ed (+). partiallv reduced (±) and lost (-) tvpes.
What is notable is that partiall1 reduced (±) tumours showed
higher serum S-ECD levels than preserved (+) tumours or lost -
tumours. In addition. E-cadherin partially reduced 1±) tumours had
more S-ECD than the others. when the cancer tissue Awas subjected
to extraction without detergent. In the previous study. both
E-cadherin partially reduced (±) and lost (-) tumours showed
similar aggressive behaviour. regarding tumour invasion and
metastasis (Oka et al. 1992). Thus. as serum S-ECD is not
increased in both E-cadherin preserved (+) and lost (-) tumours.
which have distinct tumour characteristics. S-ECD might not
affect the clinicopathological features.
As possible mechanisms for E-cadherin reduction. allelic loss
(Vessev et al. 1995). gene mutation (Becker et al. 1994) and DNA
methvlation in promoter lesions (Graff et al. 1995: Yoshiura et al.
1995) have been reported. These genomic disorders in stem cells
might be responsible for homogeneous E-cadherin reduction. but
they cannot explain the heterogeneity of E-cadherin expression
which is sometimes observed even in a small colony.
Transcriptional regulation might be another important pathway for
regulating E-cadherin expression. in which g-rowth factors (Caulin
et al. 1995). hormones (Carruba et al. 1995) or low molecule G-
protein (Tak-aishi et al. 1997) are implicated. However. the observa-
tions of this study strongly suggest a third possibility that protein
stabilitv of E-cadherin might be impaired. especially in E-cadherin
(± tumours with hi2h serum S-ECD. Cleavage by trypsin produced
S-ECD in the expenrment of a cultured cell line (Damsky et al.
1983). Trvpsin-like protease activity is detected in gastric cancer
(Koshikawa et al. 1992) and other various proteases are stimulated
in cancer. Thus. proteolIsis of E-cadherin. which is reported in
embrvos (Pev-rieras et al. 1983). migaht be involved in aastric cancer
in vivo. At the same time. we have to pay attention to the chanaing
of extracellular calcium. as sensitivity ofE-cadherin to proteolvsis
is stronaly affected by the extracellular calcium (Ozawa et al.
1990). Thus. identifying the E-cadherin protease in cancer tissue
miaht be necessarv in the future to understand the E-cadherin
reduction and S-ECD production in cancers in vivo.
The detection of S-ECD has many possible applications in both
basic and clinical research. Mass screenina studies of serum
S-ECD can be done to establish the specificity of increased serum
S-ECD for cancer patients and to demonstrate the possibility of
clinical application of serum S-ECD measurement. In addition.
S-ECD in cancer tissue is associated with E-cadherin reduction and
tumour invasion. For example. we have found that more S-ECD is
detected in the invadinc area than in the centre of the tumour
(unpublished observation). Thus. S-ECD is not just a degraded
protein fragment ofE-cadherin. Ifits mechanism ofproduction can
be revealed. S-ECD may serve as an important tool against cancer.
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